<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Experimental medicine &#8211; Birmingham Health Partners</title>
	<atom:link href="https://birminghamhealthpartners.co.uk/category/experimental-medicine/feed/" rel="self" type="application/rss+xml" />
	<link>https://birminghamhealthpartners.co.uk</link>
	<description>Strategic clinical-academic research partnership</description>
	<lastBuildDate>Tue, 23 Jun 2026 11:51:58 +0000</lastBuildDate>
	<language>en-GB</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://birminghamhealthpartners.co.uk/wp-content/uploads/2018/11/cropped-BHP_Twitter-profile-400x400-32x32.jpg</url>
	<title>Experimental medicine &#8211; Birmingham Health Partners</title>
	<link>https://birminghamhealthpartners.co.uk</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Drug to delay Type 1 Diabetes approved by NICE</title>
		<link>https://birminghamhealthpartners.co.uk/drug-to-delay-type-1-diabetes-approved-by-nice/</link>
		
		<dc:creator><![CDATA[Louise Stanley]]></dc:creator>
		<pubDate>Tue, 23 Jun 2026 11:51:58 +0000</pubDate>
				<category><![CDATA[Birmingham Health Partners]]></category>
		<category><![CDATA[Early diagnosis and detection]]></category>
		<category><![CDATA[Experimental medicine]]></category>
		<guid isPermaLink="false">https://birminghamhealthpartners.co.uk/?p=12037</guid>

					<description><![CDATA[Diabetes experts from across Birmingham Health Partners have welcomed the approval of teplizumab for use on the NHS, following an announcement by the National Institute for Health and Care Excellence (NICE). The immunotherapy drug can delay the progression to symptomatic type 1 diabetes in people who are in stage 2 of the condition, and will now [&#8230;]]]></description>
		
		
		
			</item>
		<item>
		<title>NIHR funds life-saving treatments and faster diagnosis at BWC</title>
		<link>https://birminghamhealthpartners.co.uk/nihr-funds-life-saving-treatments-and-faster-diagnosis-at-bwc/</link>
		
		<dc:creator><![CDATA[Louise Stanley]]></dc:creator>
		<pubDate>Tue, 24 Mar 2026 15:43:15 +0000</pubDate>
				<category><![CDATA[Clinical trials]]></category>
		<category><![CDATA[Early diagnosis and detection]]></category>
		<category><![CDATA[Experimental medicine]]></category>
		<guid isPermaLink="false">https://birminghamhealthpartners.co.uk/?p=11936</guid>

					<description><![CDATA[Funding of £1.5m has been awarded to BHP founder-member Birmingham Women&#8217;s and Children&#8217;s NHS Foundation Trust &#8211; enabling quicker access to life-saving treatments and faster diagnosis of rare and infectious diseases.  This National Institute for Health and Care Research (NIHR) funding boost will be used for two crucial initiatives: building a specialised Aseptic Pharmacy Unit for clinical trials, [&#8230;]]]></description>
		
		
		
			</item>
		<item>
		<title>Birmingham anti-cancer project boosted by SPARK The Midlands</title>
		<link>https://birminghamhealthpartners.co.uk/birmingham-anti-cancer-project-boosted-by-spark-the-midlands/</link>
		
		<dc:creator><![CDATA[Louise Stanley]]></dc:creator>
		<pubDate>Tue, 24 Feb 2026 14:57:02 +0000</pubDate>
				<category><![CDATA[Cancer outcomes]]></category>
		<category><![CDATA[Clinical trials]]></category>
		<category><![CDATA[Experimental medicine]]></category>
		<guid isPermaLink="false">https://birminghamhealthpartners.co.uk/?p=11918</guid>

					<description><![CDATA[A cross-BHP team from the Royal Orthopaedic Hospital NHS Foundation Trust (ROH) and Aston University has won a place on the SPARK The Midlands programme to help further the development of its minimally-invasive, anti-cancer and bone regenerative injectable paste, which uses the cancer-killing properties of gallium. SPARK The Midlands provides specialist technical and academic support to advance [&#8230;]]]></description>
		
		
		
			</item>
		<item>
		<title>Birmingham trial aims to manage arthritis as a side effect of cancer treatment</title>
		<link>https://birminghamhealthpartners.co.uk/birmingham-trial-aims-to-manage-arthritis-as-a-side-effect-of-cancer-treatment/</link>
		
		<dc:creator><![CDATA[Louise Stanley]]></dc:creator>
		<pubDate>Tue, 17 Feb 2026 12:49:00 +0000</pubDate>
				<category><![CDATA[Cancer outcomes]]></category>
		<category><![CDATA[Clinical trials]]></category>
		<category><![CDATA[Experimental medicine]]></category>
		<category><![CDATA[Inflammation and chronic disease]]></category>
		<guid isPermaLink="false">https://birminghamhealthpartners.co.uk/?p=11897</guid>

					<description><![CDATA[A UK-first trial led by Birmingham researchers aims to improve treatment of arthritis in people who have developed the condition as a result of cancer immunotherapy. The REmission induction of Arthritis caused by Cancer ImmunoTherapy (REACT) trial, led by the University of Birmingham and delivered through the National Institute for Health and Care Research (NIHR) [&#8230;]]]></description>
		
		
		
			</item>
		<item>
		<title>Trial to investigate weight loss drugs for treating blinding headache condition</title>
		<link>https://birminghamhealthpartners.co.uk/trial-to-investigate-weight-loss-drugs-for-treating-blinding-headache-condition/</link>
		
		<dc:creator><![CDATA[Louise Stanley]]></dc:creator>
		<pubDate>Wed, 11 Feb 2026 10:59:02 +0000</pubDate>
				<category><![CDATA[Clinical trials]]></category>
		<category><![CDATA[Experimental medicine]]></category>
		<category><![CDATA[Inflammation and chronic disease]]></category>
		<guid isPermaLink="false">https://birminghamhealthpartners.co.uk/?p=11866</guid>

					<description><![CDATA[Patients with Idiopathic Intracranial Hypertension (IIH), which causes headaches and potential sight loss, are being invited to take part in new research investigating the impact of weight loss drugs on their condition and eye health. The IIH Advance trial, coordinated by clinical academics at BHP founder-member the University of Birmingham, aims to recruit 86 people with IIH [&#8230;]]]></description>
		
		
		
			</item>
		<item>
		<title>Birmingham joins £50m MRC Centre for clinical trial innovation</title>
		<link>https://birminghamhealthpartners.co.uk/birmingham-joins-50m-mrc-centre-for-clinical-trial-innovation/</link>
		
		<dc:creator><![CDATA[Louise Stanley]]></dc:creator>
		<pubDate>Mon, 05 Jan 2026 12:34:30 +0000</pubDate>
				<category><![CDATA[Clinical trials]]></category>
		<category><![CDATA[Experimental medicine]]></category>
		<guid isPermaLink="false">https://birminghamhealthpartners.co.uk/?p=11774</guid>

					<description><![CDATA[Academics at BHP founder-member the University of Birmingham will be part of a new Medical Research Council Centre of Research Excellence in Clinical Trial Innovation (MRC CoRE) which aims to speed up patient and participant access to new medicines and trials, for improved patient care. The Centre, in partnership with the National Institute for Health [&#8230;]]]></description>
		
		
		
			</item>
	</channel>
</rss>
